$347 Billion Johnson & Johnson Buys Central Nervous System Biopharmaceutical Company Intra-Cellular Therapies for $14.6 Billion, Intra-Cellular Therapies Founded in 2002 by Sharon Mates
14th January 2025 | Hong Kong
Johnson & Johnson ($347 billion market value) has announced to buy central nervous system biopharmaceutical company Intra-Cellular Therapies for $14.6 billion. Intra-Cellular Therapies was founded in 2002 by Sharon Mates. Announcement (13/1/25): “Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion.” Intra-Cellular Therapies – Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel Prize-winning research that allows us to understand how therapies affect the inner workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. Johnson & Johnson – At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
“ $347 Billion Johnson & Johnson Buys Central Nervous System Biopharmaceutical Company Intra-Cellular Therapies for $14.6 Billion, Intra-Cellular Therapies Founded in 2002 by Sharon Mates “
$347 Billion Johnson & Johnson Buys Central Nervous System Biopharmaceutical Company Intra-Cellular Therapies for $14.6 Billion, Intra-Cellular Therapies Founded in 2002 by Sharon Mates
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
